┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:21 UTC APPEARANCES ......... 12 ANNOTATIONS KNOWN ALIASES ....... 2 └──────────────────────────────────────────────────────────────┘
GlaxoSmithKline (GSK)
ALSO APPEARS AS
- GSK
- GlaxoSmithKline (GSK)
APPEARS IN THE MARGINS OF
- Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias
Study 329 was an eight-week, placebo-controlled, double-blind randomized clinical trial of paroxetine (Paxil/Seroxat) in adolescents with depression, conducted in the late 1990s and published in 2001.…
- GSK Contractual Restrictions on Paroxetine Research Publication
This investigation concerns whether GlaxoSmithKline (GSK) contractually restricted Martin Keller's ability to publish findings unfavorable to the antidepressant paroxetine (marketed as Paxil/Seroxat),…
- Eliot Spitzer vs. GlaxoSmithKline Lawsuit: Research Contracts and Publication Restrictions (2004)
In 2004, then-New York Attorney General Eliot Spitzer filed a lawsuit against GlaxoSmithKline (GSK) concerning the alleged suppression of negative research findings related to the antidepressant Paxil…
- GSK Paroxetine Trials: Publication Rights and Ghostwriting Agreements
This dossier investigates the availability of contractual agreements between GlaxoSmithKline (GSK) and individual researchers, such as Martin Keller, involved in paroxetine clinical trials, particular…
- SmithKline Beecham Study 329 Adverse Event Data Submission to FDA
Study 329 was a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, conducted by SmithKline Beecham (now GlaxoSmithKline - GSK). The original published report in 2001 p…
- Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- GSK Whistleblower Claims: Suppression of Unfavorable Research Findings
This dossier investigates claims that GlaxoSmithKline (GSK) engaged in policies or practices that restricted researchers' ability to publish unfavorable findings, particularly those related to drug ef…
- Medical Guidance on Paroxetine for Adolescents and Study 329 Reference (2001-2015)
Following the 2001 publication of Study 329, an influential clinical trial on the antidepressant paroxetine (Paxil/Seroxat) for adolescent depression, questions arose regarding its efficacy and safety…
- GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015)
This dossier investigates the financial impact on GlaxoSmithKline (GSK) from adolescent paroxetine prescriptions between 2001 and 2015, following the publication of Study 329. Study 329, published in …
- Study 329's Impact on Adolescent Antidepressant Prescriptions
Study 329, a clinical trial evaluating paroxetine and imipramine for adolescent major depression, was originally published in 2001, claiming efficacy and safety for paroxetine [1]. This original publi…
- Study 329: Allegations of Ghostwriting in Paroxetine Clinical Trial
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline or GSK) between 1994 and 1998 to evaluate the efficacy of paroxetine (Paxil) in adolescents with major depressive di…